
- With Mayo Clinic emeritus internist
Edward C. Rosenow III, M.D.
read biographyclose windowBiography of
Edward C. Rosenow III, M.D.
Edward C. Rosenow III, M.D.
Dr. Edward Rosenow III sees a natural link between the Information Age and health care as a way to promote better health. Dr. Rosenow, a Columbus, Ohio, native, is board certified in internal medicine and pulmonary disease and worked in the Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minn. He retired from clinical practice in 1996 after 30 years' service at Mayo Clinic.
"It has always been my feeling that the better informed the patient is about his or her body and its functions, the better the patient-physician partnership," he says. "The informed patient is in turn more compliant with the physician's recommendations and better able to make intelligent decisions about health care needs."
Dr. Rosenow is a former Arthur M. and Gladys D. Gray Professor of Medicine and former chair of the Division of Pulmonary and Critical Care Medicine at Mayo Clinic. He was also president of the American College of Chest Physicians, consultant to NASA on the Space Station Freedom project, president of the Mayo Clinic staff, a regent with the American College of Chest Physicians and program director of the internal medicine residency program at Mayo Clinic.
During his distinguished career, Dr. Rosenow was a five-time Teacher of the Year in internal medicine and inducted into the Mayo Fellows Hall of Fame of Outstanding Teachers.
In 1994, he won the Distinguished Mayo Clinician Award from Mayo Clinic staff and in 1995 was honored with the Ralph O. Claypoole Sr. Memorial Award for Lifetime Dedication to Patient Care by the American College of Physicians. He was named to a mastership by the American College of Physicians in 1998 and that year also won the Mayo Foundation Distinguished Alumnus Award. He is also a Master Fellow in the American College of Chest Physicians. In 2008, a professorship was established in his name — the Edward C. Rosenow III, M.D., Mayo Professorship in the Art of Medicine.
Dr. Rosenow has contributed to 156 publications, including 48 book chapters and one co-authored book.
Mayo Clinic Health Manager
Get free personalized health guidance for you and your family.
Get StartedQuestion
Bronchitol: A new treatment for cystic fibrosis?
What can you tell me about a new drug called Bronchitol for cystic fibrosis?
Answer
from Edward C. Rosenow III, M.D.
Bronchitol is an inhaled, dry powder form of mannitol, a simple sugar. It's still in phase III clinical trials for treatment of excess mucus problems in conditions of the lower airways — specifically cystic fibrosis, bronchiectasis and some forms of chronic bronchitis that are associated with excess mucus. Bronchitol is thought to loosen and thin secretions in the airways so that they can be coughed out more easily. However, Bronchitol doesn't replace usual measures for treating these conditions, such as antibiotics, postural drainage and bronchodilators.
Although early results look promising, researchers will need at least another year to fully evaluate Bronchitol's effectiveness and safety.